Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Eurofins Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Eurofins Discovery Extends AI-powered Integrated Drug Discovery Collaboration
Details : The collaboration aims to combine strengths of Eurofins Discovery’s DiscoveryOne comprehensive Integrated Drug Discovery capabilities with Dompé’s powerful supercomputing AI platform.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Eurofins Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : Aramis Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.
Brand Name : A197
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Aramis Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Reparixin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2022
Lead Product(s) : Reparixin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Engitix Therapeutics
Deal Size : $54.0 million
Deal Type : Series A Financing
Details : The financing will be used to invest in Engitix’s internal drug discovery pipeline through IND-enabling studies, expand its ECM discovery platform and bioinformatics capabilities into new therapeutic areas, and to expand its team, facilities and operat...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Engitix Therapeutics
Deal Size : $54.0 million
Deal Type : Series A Financing
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : FarmaMondo
Deal Size : Undisclosed
Deal Type : Agreement
Details : Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other ...
Brand Name : Oxervate
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 26, 2020
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : FarmaMondo
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Reparixin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ANVISA Authorizes Dompé's REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients
Details : The REPAVID-19 clinical trial will evaluate efficacy and safety of Dompé’s Reparixin in hospitalized adult patients with severe COVID-19 pneumonia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 01, 2020
Lead Product(s) : Reparixin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Tanner Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®
Details : The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikista...
Brand Name : Oxervate
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Tanner Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ladarixin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes
Details : Results from Phase 2 trial demonstrate that ladarixin, a novel small molecule that inhibits the biological activity of IL-8, has potential activity in the preservation of β-cell function in new-onset type 1 diabetes (T1D).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2020
Lead Product(s) : Ladarixin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?